Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT02745769 |
Title | A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents |
Recruitment | Completed |
Gender | both |
Phase | Phase I |
Variant Requirements | No |
Sponsors | Eli Lilly and Company |
Indications | |
Therapies | |
Age Groups: | adult |
Covered Countries | USA | GBR | FRA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
UAB Comprehensive Cancer Center | Birmingham | Alabama | 35249 | United States | Details | |
University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | United States | Details | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lyon | 69373 | France | Details | ||
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Marseille | 13385 | France | Details | ||
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | London | SE1 9RT | United Kingdom | Details |